References
- Coates A, Abraham S, Kaye S B, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983; 19: 203–8
- Cubeddu L X, Hoffmann I S, Fuenmayor N T, Finn A L. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin induced nausea and vomiting. N Engl J Med 1990; 322: 810–6
- Richardson B P, Engel G, Donatsch P, Stadler P A. Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature 1985; 316: 126–31
- Kilpatrick G J, Jones B J, Tyers M B. The identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746–8
- Marty M, Pouillart P, School S, et al. Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin induced emesis. N Engl J Med 1990; 322: 816–21
- DeMulder H M, Seynaeve C, Vermorken J B, et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834–40
- Smith D B, Newlands E S, Rustin G J, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991; 338: 487–90
- Schmoll H J. The role of ondansetron in the treatment of emesis induced by non-cisplatin-containing chemotherapy regimens. Eur J Cancer Clin Oncol 1989; 25((Supp. l))S35–9
- Jones A L, Hill A S, Soukoup M, et al. Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderably emetogenic chemotherapy. Lancet 1991; 338: 483–7